MX2020000190A - Métodos para tratar la insuficiencia cardíaca con activadores de sarcómero cardíaco. - Google Patents

Métodos para tratar la insuficiencia cardíaca con activadores de sarcómero cardíaco.

Info

Publication number
MX2020000190A
MX2020000190A MX2020000190A MX2020000190A MX2020000190A MX 2020000190 A MX2020000190 A MX 2020000190A MX 2020000190 A MX2020000190 A MX 2020000190A MX 2020000190 A MX2020000190 A MX 2020000190A MX 2020000190 A MX2020000190 A MX 2020000190A
Authority
MX
Mexico
Prior art keywords
methods
heart failure
activators
treating heart
cardiac sarcomere
Prior art date
Application number
MX2020000190A
Other languages
English (en)
Spanish (es)
Inventor
Narimon Honarpour
Malik Fady
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2020000190A publication Critical patent/MX2020000190A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2020000190A 2017-06-30 2018-06-29 Métodos para tratar la insuficiencia cardíaca con activadores de sarcómero cardíaco. MX2020000190A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762527983P 2017-06-30 2017-06-30
PCT/US2018/040181 WO2019006235A1 (en) 2017-06-30 2018-06-29 METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS

Publications (1)

Publication Number Publication Date
MX2020000190A true MX2020000190A (es) 2020-07-22

Family

ID=63013097

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020000190A MX2020000190A (es) 2017-06-30 2018-06-29 Métodos para tratar la insuficiencia cardíaca con activadores de sarcómero cardíaco.
MX2022015115A MX2022015115A (es) 2017-06-30 2020-01-08 Metodos para tratar la insuficiencia cardiaca con activadores de sarcomeros cardiacos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022015115A MX2022015115A (es) 2017-06-30 2020-01-08 Metodos para tratar la insuficiencia cardiaca con activadores de sarcomeros cardiacos.

Country Status (22)

Country Link
US (4) US11576910B2 (cg-RX-API-DMAC10.html)
EP (2) EP4512470A3 (cg-RX-API-DMAC10.html)
JP (3) JP2020526483A (cg-RX-API-DMAC10.html)
CN (1) CN110996953A (cg-RX-API-DMAC10.html)
AU (2) AU2018290983B2 (cg-RX-API-DMAC10.html)
BR (1) BR112019028046A2 (cg-RX-API-DMAC10.html)
CA (1) CA3068588A1 (cg-RX-API-DMAC10.html)
DK (1) DK3645002T3 (cg-RX-API-DMAC10.html)
ES (1) ES3008457T3 (cg-RX-API-DMAC10.html)
FI (1) FI3645002T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20241729T1 (cg-RX-API-DMAC10.html)
HU (1) HUE069805T2 (cg-RX-API-DMAC10.html)
LT (1) LT3645002T (cg-RX-API-DMAC10.html)
MA (1) MA49508B1 (cg-RX-API-DMAC10.html)
MD (1) MD3645002T2 (cg-RX-API-DMAC10.html)
MX (2) MX2020000190A (cg-RX-API-DMAC10.html)
PL (1) PL3645002T3 (cg-RX-API-DMAC10.html)
PT (1) PT3645002T (cg-RX-API-DMAC10.html)
RS (1) RS66581B1 (cg-RX-API-DMAC10.html)
SI (1) SI3645002T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202500067T1 (cg-RX-API-DMAC10.html)
WO (1) WO2019006235A1 (cg-RX-API-DMAC10.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12194039B2 (en) 2020-11-12 2025-01-14 Amgen Inc Methods of treating heart failure by administering omecamtiv mecarbil
US12295952B2 (en) 2017-06-30 2025-05-13 Cytokinetics, Inc. Methods of treating heart failure with cardiac sarcomere activators

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3821882A1 (en) 2013-03-14 2021-05-19 Amgen Inc. Heterocyclic compounds and their uses
MX2021009594A (es) 2017-06-30 2022-10-24 Amgen Inc Sintesis de omecamtiv mecarbil.
DK3594199T3 (da) 2018-07-09 2020-09-14 Fis Fabbrica Italiana Sintetici Spa Krystallinsk 2-flour-3-nitrotoluen og proces til forberedelse deraf
EP3837009A1 (en) 2018-08-17 2021-06-23 Amgen, Inc Salts and crystal forms of omecamtiv mecarbil
SG11202112723PA (en) * 2019-05-19 2021-12-30 Myokardia Inc Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide
MX2022000498A (es) 2019-07-17 2022-02-03 Cytokinetics Inc Polimorfos de (r)-n-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihi dro-1h-inden-1-il) -2-metil-2h- tetrazol-5-carboxamida.
WO2021163172A1 (en) * 2020-02-10 2021-08-19 Amgen Inc. Omecamtiv mecarbil tablet
JP7832128B2 (ja) * 2020-06-15 2026-03-17 マイオカーディア，インク 心房機能不全の治療
CN116710139A (zh) * 2020-11-12 2023-09-05 安进股份有限公司 通过施用奥美卡替莫卡必尔治疗心力衰竭的方法
AU2022232919A1 (en) 2021-03-10 2023-10-19 Amgen Inc. Synthesis of omecamtiv mecarbil
WO2023164452A2 (en) * 2022-02-22 2023-08-31 Yale University Methods of treating, ameliorating, or preventing heart failure, and methods of promoting heart muscle growth
CA3268270A1 (en) 2022-09-26 2024-04-04 Edgewise Therapeutics, Inc. 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND ASSOCIATED USES
WO2024081611A1 (en) * 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
JP7858148B1 (ja) 2023-03-27 2026-05-13 エッジワイズ セラピューティクス， インコーポレイテッド キナゾリンジオン化合物およびその使用
KR20250174911A (ko) 2023-03-27 2025-12-15 엣지와이즈 테라퓨틱스, 인크. 퀴놀리논 아미드 화합물 및 이의 용도
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
WO2026050494A1 (en) 2024-08-29 2026-03-05 Cytokinetics, Incorporated Omecamtiv mecarbil for use in treating heart failure by activating cardiac sarcomere

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
WO1999040942A1 (en) 1998-02-10 1999-08-19 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
WO2004033036A2 (en) 2002-10-04 2004-04-22 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
US7507735B2 (en) 2004-06-17 2009-03-24 Cytokinetics, Inc. Compounds, compositions and methods
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
CA2651283A1 (en) 2006-05-15 2007-11-22 Wisconsin Alumni Research Foundation Pulmonary delivery of 1.alpha.,25-dihydroxyvitamin d3 and co-administration of parathyroid hormone or calcitonin
FR2902092B1 (fr) 2006-06-07 2008-09-05 Sapelem Soc Par Actions Simpli Appareil de manutention de charge
WO2008130158A1 (en) 2007-04-19 2008-10-30 Dong-A Pharmaceutical. Co., Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
EP3821882A1 (en) 2013-03-14 2021-05-19 Amgen Inc. Heterocyclic compounds and their uses
JP6634368B2 (ja) * 2013-03-14 2020-01-22 アムジエン・インコーポレーテツド 複素環式化合物及びそれらの使用
EP3250557B1 (en) 2015-01-29 2024-11-20 Signal Pharmaceuticals, LLC Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
JP6858716B2 (ja) 2015-06-26 2021-04-14 アムジエン・インコーポレーテツド 心筋ミオシン活性化剤と洞房結節Ｉｆ電流阻害剤の併用療法
AU2018214629A1 (en) 2017-02-06 2019-08-22 Acceleron Pharma Inc. Compositions and methods for treating heart failure
JP2020526483A (ja) 2017-06-30 2020-08-31 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法
MX2021009594A (es) 2017-06-30 2022-10-24 Amgen Inc Sintesis de omecamtiv mecarbil.
DK3594199T3 (da) 2018-07-09 2020-09-14 Fis Fabbrica Italiana Sintetici Spa Krystallinsk 2-flour-3-nitrotoluen og proces til forberedelse deraf
WO2020014406A1 (en) 2018-07-12 2020-01-16 Assia Chemical Industries Ltd. Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
EP3599243B1 (en) 2018-07-26 2023-04-12 CVIE Therapeutics Limited 17beta-heterocyclyl-digitalis like compounds for the treatment of heart failure
EP3837009A1 (en) 2018-08-17 2021-06-23 Amgen, Inc Salts and crystal forms of omecamtiv mecarbil
US12442027B2 (en) 2018-12-18 2025-10-14 Amgen Inc. Method of reducing aromatic nitro compounds
CN112118846B (zh) 2019-03-05 2024-04-16 风树疗法公司 治疗急性心力衰竭(ahf)用的含伊司他肟的静脉内制剂
US20220340542A1 (en) 2019-09-19 2022-10-27 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
US20220348543A1 (en) 2019-09-19 2022-11-03 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
WO2021070123A1 (en) 2019-10-09 2021-04-15 Dr. Reddy’S Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
US20220411374A1 (en) 2019-10-09 2022-12-29 Dr. Reddy's Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
CA3157629A1 (en) 2019-11-10 2021-05-14 MyoKardia, Inc. Methods of treatment with myosin modulator
GB201918853D0 (en) 2019-12-19 2020-02-05 Lund Lars H Methods of treatment
CN114929671B (zh) 2020-01-03 2024-04-16 苏州科睿思制药有限公司 化合物i二盐酸盐的共晶及其制备方法和用途
WO2021163172A1 (en) 2020-02-10 2021-08-19 Amgen Inc. Omecamtiv mecarbil tablet
IL302850A (en) 2020-11-12 2023-07-01 Amgen Inc Methods of treating heart failure by administering OMECAMTIV MECARBIL
AU2022232919A1 (en) 2021-03-10 2023-10-19 Amgen Inc. Synthesis of omecamtiv mecarbil
WO2023205291A2 (en) 2022-04-21 2023-10-26 The Board Of Regents Of The University Of Oklahoma Targeting myocardial tissue for delivery of therapeutic and imaging agents
WO2024081611A1 (en) 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
US11986474B1 (en) * 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12295952B2 (en) 2017-06-30 2025-05-13 Cytokinetics, Inc. Methods of treating heart failure with cardiac sarcomere activators
US12194039B2 (en) 2020-11-12 2025-01-14 Amgen Inc Methods of treating heart failure by administering omecamtiv mecarbil

Also Published As

Publication number Publication date
MD3645002T2 (ro) 2025-04-30
CN110996953A (zh) 2020-04-10
MA49508B1 (fr) 2024-12-31
US11931358B2 (en) 2024-03-19
CA3068588A1 (en) 2019-01-03
HUE069805T2 (hu) 2025-04-28
FI3645002T3 (fi) 2025-01-29
US20230149394A1 (en) 2023-05-18
MA49508A (fr) 2020-05-06
US20230355615A1 (en) 2023-11-09
RS66581B1 (sr) 2025-04-30
PT3645002T (pt) 2025-01-24
EP3645002B1 (en) 2024-10-30
ES3008457T3 (en) 2025-03-24
AU2018290983A1 (en) 2020-01-23
BR112019028046A2 (pt) 2020-07-07
DK3645002T3 (da) 2024-12-16
US11576910B2 (en) 2023-02-14
LT3645002T (lt) 2025-02-10
SMT202500067T1 (it) 2025-03-12
EP3645002A1 (en) 2020-05-06
EP4512470A3 (en) 2025-04-23
JP2020526483A (ja) 2020-08-31
AU2024200991A1 (en) 2024-03-07
SI3645002T1 (sl) 2025-03-31
US12295952B2 (en) 2025-05-13
US20250255862A1 (en) 2025-08-14
EP4512470A2 (en) 2025-02-26
US20200155547A1 (en) 2020-05-21
WO2019006235A1 (en) 2019-01-03
AU2018290983B2 (en) 2023-11-23
MX2022015115A (es) 2023-01-18
AU2024200991B2 (en) 2025-04-10
JP2025165979A (ja) 2025-11-05
HRP20241729T1 (hr) 2025-03-14
PL3645002T3 (pl) 2025-03-24
JP2023088944A (ja) 2023-06-27

Similar Documents

Publication Publication Date Title
EP4512470A3 (en) Methods of treating heart failure with cardiac sarcomere activators
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
MX2025000166A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo
EP3346915A4 (en) Systems, devices, components and methods for detecting the locations of sources of cardiac rhythm disorders in a patient's heart
MX2022008868A (es) Tratamiento del cancer con tg02.
WO2018217710A8 (en) Micro-nanobubble solutions for tissue preservation and generation thereof
WO2019067666A8 (en) Therapeutic methods relating to hsp90 inhibitors
EP4252833A3 (en) Microstimulation sleep disordered breathing (sdb) therapy device
MY199581A (en) Plasminogen replacement therapy for plasminogen-deficiency
MX2016000173A (es) Sistemas y metodos para seguimiento y presentacion de datos de terapia para acufenos.
PH12019502316A1 (en) Combination cancer immunotheraphy with pentaaza macrocyclic ring complex
PH12015502794B1 (en) Pyrimidinedione compounds against cardiac conditions
MX379899B (es) Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal
MX2016009102A (es) Composiciones de enolasa 1 (eno1) y sus usos.
MX390722B (es) Tratamiento de resistencia a diureticos.
EP4252847A3 (en) Regimens and methods of treating multiple sclerosis using ofatumumab
EP4249056A3 (en) Method for treating heart failure
EA201592058A1 (ru) Применение ландиолола гидрохлорида в длительном лечении тахиаритмии
MX2020003243A (es) Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.
MX2024004333A (es) Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas.
TW201613639A (en) Methods for treating cardiovascular diseases
EP4696381A3 (en) Medicine
ZA202004657B (en) Methods of testosterone therapy
Mount et al. Tissue-engineered cardiovascular grafts and novel applications of tissue engineering by self-assembly (tesa™)
PH12017501918A1 (en) Multi-peptide composition